Immunic, Inc. (IMUX) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Immunic (IMUX) by buying shares or fractional shares at any major US broker, through a biotech or small-cap healthcare ETF that holds it, or as one holding in a thematic basket. Immunic is a late-stage biotechnology company developing oral therapies for neurologic diseases, led by vidofludimus calcium (IMU-838) in Phase 3 trials for relapsing multiple sclerosis. The single biggest thing to understand is that this is a clinical-stage biotech with no approved products yet, so its value hinges almost entirely on binary trial readouts and its ability to fund operations, which makes the stock highly speculative and prone to sharp moves on trial news.
IMUX stock price
As of 2026-07-14, Immunic, Inc. (IMUX) last closed at $15.35, up 82.8% over the past year. Over the past 52 weeks it has traded between $5.10 and $15.41.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Immunic, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Immunic, Inc. (IMUX) do?
Immunic, Inc. is a late-stage biotechnology company developing a portfolio of novel oral therapies aimed at neurologic and inflammatory diseases. Its lead program, vidofludimus calcium (IMU-838), is being tested in two large global Phase 3 trials, the ENSURE program, for relapsing multiple sclerosis, with thousands of patients enrolled and top-line data expected around the end of 2026. The drug is described as a first-in-class activator of the Nurr1 nuclear receptor, giving it a potential neuroprotective mechanism, combined with anti-inflammatory and anti-viral effects through selective inhibition of the DHODH enzyme.
As a clinical-stage company, Immunic has no approved products and therefore essentially no product revenue; it funds itself through cash raised from investors and spends heavily on research and development. In early 2026 it strengthened its balance sheet with a private placement that added roughly $187 million in net proceeds, which management said funds operations beyond twelve months. Beyond its lead multiple sclerosis program, the pipeline includes earlier-stage candidates such as IMU-856, aimed at gastrointestinal conditions, and IMU-381, part of a broader effort to build a platform across neurodegenerative and other diseases. The entire investment case rests on trial outcomes, regulatory progress, and the ability to keep funding development until a product can reach the market, if it ever does.
What's driving Immunic, Inc. (IMUX)?
1. Phase 3 multiple sclerosis readout
The central catalyst is top-line data from the two ENSURE Phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis, expected around the end of 2026. For a late-stage biotech, a pivotal readout is the single event that most defines the stock. Positive data could open a path to regulatory filing and approval, while a miss would be a major setback.
2. Differentiated mechanism
Vidofludimus calcium is positioned as a first-in-class Nurr1 activator with potential neuroprotective effects, layered on anti-inflammatory and anti-viral activity through DHODH inhibition. If that dual mechanism translates into a strong efficacy and safety profile, it could differentiate the drug in a competitive multiple sclerosis market. The mechanism's real-world value, however, will only be proven by the trial data.
3. Balance sheet and runway
A February 2026 private placement added roughly $187 million in net proceeds, which management believes funds operations beyond twelve months and through the key readout. For a company with no product revenue, cash runway is existential: enough funding to reach data without a dilutive emergency raise is a meaningful positive for shareholders.
4. Broader pipeline optionality
Beyond the lead program, Immunic is advancing earlier-stage candidates such as IMU-856 for gastrointestinal conditions and IMU-381, aiming to build a platform across neurologic and other diseases. A diversified pipeline offers additional shots on goal, so a single program's outcome does not have to define the whole company. These programs are early, however, and years from any potential approval.
What are the risks to Immunic, Inc. (IMUX)?
The dominant risk is clinical trial failure: as a company whose value rests on vidofludimus calcium, a negative or ambiguous Phase 3 readout could cut the stock severely, since there is no approved product to fall back on. Even positive data must clear regulatory review before any product can be sold, and commercialization in the competitive multiple sclerosis market is another hurdle. Because Immunic has no product revenue and spends heavily on research, it depends on raising capital, and future financings can dilute existing shareholders. The stock is thinly followed and volatile, capable of large swings on any trial, regulatory, or financing news. Timelines can slip, and earlier-stage programs remain years from potential approval. This is a speculative, binary investment suited only to investors comfortable with the possibility of significant loss.
How is Immunic, Inc. (IMUX) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Immunic, Inc.'s investor relations page or your broker.
- Product revenue: Essentially none; clinical-stage company with no approved products
- Lead program: Vidofludimus calcium (IMU-838) in two Phase 3 relapsing-MS trials (ENSURE)
- Key catalyst: Top-line Phase 3 data expected around the end of 2026
- Cash position: Boosted by a February 2026 private placement of roughly $187 million net; runway said to exceed twelve months
- Operating profile: Ongoing net losses driven by heavy research and development spending
- Valuation lens: Trades on trial expectations and cash runway, not earnings; value is event-driven
Figures are approximate and tied to the asOf date; verify live numbers before acting. Traditional valuation metrics like P/E do not apply to a clinical-stage biotech with no earnings; the stock is valued on the probability-weighted potential of its pipeline, chiefly the Phase 3 multiple sclerosis readout, against its cash runway and share count. Value here is binary and event-driven, so the stock can move dramatically on a single data point. Treat any implied valuation as a bet on trial success, not on current fundamentals.
Who competes with Immunic, Inc. (IMUX)?
Established multiple sclerosis drugmakers
The relapsing multiple sclerosis market is served by large companies with approved therapies, including Roche (Ocrevus), Novartis, Biogen, Sanofi, and Bristol Myers Squibb. If vidofludimus calcium reaches the market, it would compete against these entrenched, well-funded incumbents, making differentiation on efficacy, safety, and convenience essential.
Other clinical-stage neurology and DHODH biotechs
Immunic competes for investor capital and clinical progress with other small and mid-cap biotechs developing neurologic and immune-modulating therapies. Like Immunic, these companies trade on trial catalysts and cash runway rather than earnings, and their fortunes rise and fall on data readouts rather than on established products.
Diversified biotech exposure alternatives
Investors who want biotech exposure without single-company binary risk can use biotech ETFs that hold dozens or hundreds of names. These spread trial risk across many companies but dilute the outsized upside a successful Immunic readout could deliver, offering a lower-variance way to invest in the drug-development theme.
How to invest in Immunic, Inc. (IMUX)
There are three common ways to get IMUX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so IMUX sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where IMUX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Immunic, Inc. (IMUX)
Immunic is a high-risk, high-reward clinical-stage biotech whose value rests on late-stage multiple sclerosis trial data expected around the end of 2026 and on the strength of its balance sheet. Positive readouts could re-rate the stock sharply, while a failure could be severe. This is a binary, speculative holding, not a steady compounder.
Build a basket around IMUX with Walnut
Use Immunic, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is IMUX a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a differentiated multiple sclerosis drug nearing a pivotal Phase 3 readout with cash to reach it. The bear case is that Immunic is a clinical-stage biotech with no approved products, so a trial failure could be severe and future financings could dilute shareholders. This is a speculative, binary holding to weigh carefully against your portfolio.
What does Immunic actually do?
+
Immunic is a late-stage biotech developing oral therapies for neurologic and inflammatory diseases. Its lead drug, vidofludimus calcium, is in Phase 3 trials for relapsing multiple sclerosis, and it has earlier-stage programs like IMU-856. It has no approved products yet, so it earns essentially no product revenue and funds development through capital raised from investors.
Why is IMUX so volatile?
+
Immunic is a clinical-stage biotech with no approved products, so its value depends on binary trial outcomes rather than earnings. A single Phase 3 readout can make or break the investment case, and financings, regulatory news, and timeline changes all move the stock. Thin trading and small size amplify these swings, which is typical of development-stage biotech names.
When is Immunic's key Phase 3 data expected?
+
Immunic has guided that top-line data from its two ENSURE Phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis is expected around the end of 2026. That readout is the most important catalyst for the stock. Biotech timelines can slip, so always check the company's latest guidance before assuming a specific date.
Does Immunic have enough cash to operate?
+
A February 2026 private placement added roughly $187 million in net proceeds, which management said funds operations beyond twelve months and through the key readout. For a company with no product revenue, cash runway is critical. Future development still requires capital, however, and additional raises could dilute shareholders. Check the latest filings for current cash levels.
How does vidofludimus calcium work?
+
Vidofludimus calcium is described as a first-in-class activator of the Nurr1 nuclear receptor, giving it potential neuroprotective effects, combined with anti-inflammatory and anti-viral activity by selectively inhibiting the DHODH enzyme. The idea is to combine protection of nerve cells with control of inflammation in multiple sclerosis. Whether that mechanism delivers strong results will be settled by the Phase 3 data.
Does Immunic pay a dividend?
+
No. Immunic is a clinical-stage biotech with no approved products and ongoing net losses, so it does not pay a dividend and reinvests all resources into research and development. Investors in a company like this are betting entirely on future trial success and share-price appreciation, not on income.
What are the main risks of investing in IMUX?
+
The central risk is trial failure: with value resting on vidofludimus calcium, a negative Phase 3 readout could hit the stock hard since there is no approved product to cushion it. Even success must clear regulatory review and then compete against entrenched multiple sclerosis drugmakers. Ongoing losses mean reliance on capital raises that can dilute shareholders, and the stock is thinly traded and volatile.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Immunic, Inc.'s investor relations page or your broker before making investment decisions.